Form 4: Protagonist CEO Awarded Significant Equity Grants

Protagonist Therapeutics CEO Dinesh V. Patel received grants of 95,400 restricted stock units and 120,200 stock options on January 2, 2026.

Summary

• Dinesh V. Patel, Ph.D., President and CEO, and a Director of Protagonist Therapeutics, Inc. (PTGX), acquired 95,400 shares of common stock in the form of Restricted Stock Units (RSUs) on January 2, 2026.
• These RSUs were granted at a price of $0 and will vest in four equal annual installments on January 15, 2027, 2028, 2029, and 2030, contingent on Dr. Patel's continued service.
• Following this transaction, Dr. Patel beneficially owns 614,943 shares of common stock.
• Dr. Patel also acquired 120,200 stock options on January 2, 2026, with an exercise price of $87.18 per share.
• These stock options will vest in 48 equal monthly installments following January 2, 2026, subject to Dr. Patel's continued service.
• The stock options have an expiration date of January 2, 2036.
• Following this transaction, Dr. Patel beneficially owns 120,200 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of equity awards to the CEO is a standard practice for executive compensation, aligning management's interests with shareholders. It reflects ongoing operations and retention efforts, which is generally viewed as a neutral to slightly positive development for corporate governance and stability.

Positives

• The equity grants align the CEO's long-term interests with those of shareholders, incentivizing sustained company performance.
• The awards serve as a retention mechanism for key executive talent, ensuring leadership continuity.

Negatives

• The future exercise of stock options and vesting of RSUs could lead to a degree of share dilution for existing shareholders.

Risks

• The value of the equity awards is subject to the future market price fluctuations of Protagonist Therapeutics' common stock.
• The vesting of both RSUs and stock options is contingent upon Dr. Patel's continued service to the company; forfeiture would occur if service ceases before vesting dates.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend several years into the future, indicating an expectation of continued service from the CEO and a long-term incentive structure tied to the company's performance.

Industry Context

The granting of restricted stock units and stock options is a common practice in the biotechnology and pharmaceutical industries for executive compensation. It is designed to attract, retain, and motivate key leadership by linking their personal wealth to the long-term success and share price performance of the company.

Comparison to Industry Standards

• Equity compensation packages, including RSUs and stock options, are standard components of executive remuneration across the biotech sector, comparable to practices at companies like Amgen, Gilead Sciences, or Biogen.
• The multi-year vesting schedules (4 years for RSUs, 48 months for options) are typical for long-term incentive plans, aiming to foster sustained commitment and performance, aligning with best practices in corporate governance for executive retention.

Related Party Transactions

• The grants of restricted stock units and stock options to Dinesh V. Patel, the President and CEO, constitute a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of equity awards, but also benefit from increased alignment of CEO's interests with long-term share price performance.
• Employees: May signal stability in leadership and a commitment to executive retention.
• Management: Provides significant long-term incentives and compensation tied to company performance.

Next Steps

• The restricted stock units will vest in four equal annual installments on January 15, 2027, 2028, 2029, and 2030.
• The stock options will vest in 48 equal monthly installments following January 2, 2026.

Key Dates

Recommendation

This Form 4 filing reports routine equity compensation for the CEO, which is a standard practice for public companies. It does not contain information that would fundamentally alter the investment thesis for Protagonist Therapeutics, nor does it suggest any immediate catalysts for significant share price movement. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals and market conditions rather than this specific insider transaction.

Keywords

Protagonist Therapeutics, PTGX, SEC Form 4, Insider Transaction, Equity Award, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Dinesh V. Patel